These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32725345)

  • 1. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies.
    Zhang X; Wu Q; Wei M; Deng X; Gu C; Wang Z
    Int J Colorectal Dis; 2020 Oct; 35(10):1831-1839. PubMed ID: 32725345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
    Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
    Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
    Delhorme JB; Sauvinet G; Séverac F; Diab S; Liu D; Rohr S; Romain B; Brigand C
    Ann Surg Oncol; 2022 Nov; 29(12):7568-7576. PubMed ID: 35882692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
    Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
    J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
    Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
    J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
    Woeste MR; Philips P; Egger ME; Scoggins CR; McMasters KM; Martin RCG
    J Surg Oncol; 2020 Jun; 121(8):1298-1305. PubMed ID: 32239529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
    Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
    J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
    Benzaquen E; Wang Y; Wiseman S; Rosenfeld V; Sideris L; Dubé P; Pelletier JS; Vanounou T
    Can J Surg; 2021 Mar; 64(2):E111-E118. PubMed ID: 33651573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
    Narasimhan V; Warrier S; Michael M; Ramsay R; Heriot A
    J Gastrointest Surg; 2020 Sep; 24(9):2104-2112. PubMed ID: 31745907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO
    Rotolo S; Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Pacelli F
    Updates Surg; 2021 Aug; 73(4):1443-1448. PubMed ID: 33782856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
    Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA
    Ann Surg Oncol; 2023 Apr; 30(4):2486-2493. PubMed ID: 36484904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
    Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
    Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
    Glockzin G; Gerken M; Lang SA; Klinkhammer-Schalke M; Piso P; Schlitt HJ
    BMC Cancer; 2014 Nov; 14():807. PubMed ID: 25369730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
    Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
    BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.